dov-216,303 dov-216,303 dov 216,303 is an experimental antidepressant drug originally developed by dov pharmaceutical and was licensed to merck & co. in 2004; merck and dov terminated their relationship in december 2006.: 12 dov-216,303legal statuslegal status us: investigational new drug identifiers iupac name 1-(3,4-dichlorophenyl)-3-azabicyclohexane cas number66504-40-3 npubchem cid9795276chemspider7971043 nunii5w2ya6f455chemblchembl528995 nchemical and physical dataformulac11h11cl2nmolar mass228.12 g·mol−13d model (jsmol)interactive image smiles c1c2c1(cnc2)c3=cc(=c(c=c3)cl)cl inchi inchi=1s/c11h11cl2n/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14h,4-6h2 nkey:bsmnrycsbfhemq-uhfffaoysa-n n ny (what is this?) (verify) it is a triple reuptake inhibitor (tri), or serotonin-norepinephrine-dopamine reuptake inhibitor (sndri). it is the racemic mixture of amitifadine (dov-21,947) and its (–)-enantiomer, dov-102,677. its ic50 values for sert, net, and dat are ki 14 nm, 20 nm, and 78 nm, respectively. as of march 2008, dov had no intention to further develop dov-216,303 because the patent on the compound had expired.: 6 in a mouse model, dov-216,303 has shown the ability to promote recovery after spinal cord contusion.